AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Rock Bottom Prices May Tempt Big Pharma
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
You may also be interested in...
Bellicum Weighs Options After Hitting Brakes On CAR-T Program
An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.
How To Turn Around A Struggling Biotech
Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.
Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.